ECCO 第七次科学研讨会：炎症性肠病的精准医学——疾病结局和治疗反应。
Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.
机构信息
University Hospitals Leuven Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.
KU Leuven Department of Chronic Diseases and Metabolism, Translational Research Center for Gastrointestinal Disorders [TARGID], Leuven, Belgium.
出版信息
J Crohns Colitis. 2021 Sep 25;15(9):1431-1442. doi: 10.1093/ecco-jcc/jjab050.
Abstract
Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.
摘要
炎症性肠病（IBD）是一个具有两个极端表型的异质谱，即克罗恩病（CD）和溃疡性结肠炎（UC），它们都代表了许多表型的变化。因此，我们不应该再以同样的方式对待所有的 IBD 患者，而是应该重新思考临床分类，并修改治疗方案，为 IBD 进入精准医学时代做好准备。本次 ECCO 科学研讨会旨在提供预后和预测标志物的最新概述，阐明生物标志物开发中的关键问题，提出 IBD 生物标志物开发的最佳实践（包括试验设计），并讨论多组学数据整合的潜力，以帮助推动进一步的进展，使精准医学在 IBD 中成为现实。
相似文献
1
Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.ECCO 第七次科学研讨会：炎症性肠病的精准医学——疾病结局和治疗反应。
J Crohns Colitis. 2021 Sep 25;15(9):1431-1442. doi: 10.1093/ecco-jcc/jjab050.
2
Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-What, Why, and How.ECCO 第七次科学研讨会成果：炎症性肠病精准医学——是什么、为什么以及如何实现。
J Crohns Colitis. 2021 Sep 25;15(9):1410-1430. doi: 10.1093/ecco-jcc/jjab051.
3
Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Prediction and Prevention of Inflammatory Bowel Disease.ECCO 第七届科学研讨会成果：炎症性肠病的精准医学——预测和预防。
J Crohns Colitis. 2021 Sep 25;15(9):1443-1454. doi: 10.1093/ecco-jcc/jjab048.
4
Challenges in IBD Research: Precision Medicine.炎症性肠病研究的挑战：精准医学。
Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S31-S39. doi: 10.1093/ibd/izz078.
5
Impact of artificial intelligence on prognosis, shared decision-making, and precision medicine for patients with inflammatory bowel disease: a perspective and expert opinion.人工智能对炎症性肠病患者预后、共同决策和精准医学的影响：观点和专家意见。
Ann Med. 2023;55(2):2300670. doi: 10.1080/07853890.2023.2300670. Epub 2024 Jan 1.
6
Precision Medicine in Pediatric Inflammatory Bowel Disease.精准医学在小儿炎症性肠病中的应用
Pediatr Clin North Am. 2021 Dec;68(6):1171-1190. doi: 10.1016/j.pcl.2021.07.011.
7
Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD - Challenges and Future Directions.欧洲克罗恩病和结肠炎组织第七次科学研讨会成果：炎症性肠病的精准医学——挑战与未来方向
J Crohns Colitis. 2021 Sep 25;15(9):1407-1409. doi: 10.1093/ecco-jcc/jjab049.
8
Integration and implementation of precision medicine in the multifaceted inflammatory bowel disease.精准医学在多方面炎症性肠病中的整合与实施。
World J Gastroenterol. 2023 Sep 28;29(36):5211-5225. doi: 10.3748/wjg.v29.i36.5211.
9
Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification.蛋白质组学和脂质组学在炎症性肠病研究中的应用：从机制研究到生物标志物的发现。
Int J Mol Sci. 2018 Sep 15;19(9):2775. doi: 10.3390/ijms19092775.
10
Novel biomarker profiles to improve individual diagnosis and prognosis in patients with suspected inflammatory bowel disease: protocol for the Nordic inception cohort study (NORDTREAT).新型生物标志物谱可改善疑似炎症性肠病患者的个体诊断和预后：北欧发病队列研究（NORDTREAT）方案。
BMJ Open. 2024 May 15;14(5):e083144. doi: 10.1136/bmjopen-2023-083144.
引用本文的文献
1
Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort study.临床前炎症性肠病的自然史、免疫学及遗传学特征（EARLY）：一项前瞻性队列研究的研究方案
Therap Adv Gastroenterol. 2025 May 12;18:17562848251338647. doi: 10.1177/17562848251338647. eCollection 2025.
2
Care needs profiles of Crohn's disease patients and their associations with symptom clusters, post-traumatic growth, and family function: a latent profile analysis.克罗恩病患者的护理需求概况及其与症状群、创伤后成长和家庭功能的关联：一项潜在概况分析
BMC Gastroenterol. 2025 May 9;25(1):351. doi: 10.1186/s12876-025-03953-5.
3
Characterization of the Regulatory Landscape in Crohn's Disease Reveals microRNA-Associated Alterations that Shape Anti-TNF Response.克罗恩病调控格局的特征揭示了影响抗TNF反应的微小RNA相关改变。
Inflamm Bowel Dis. 2025 Mar 11. doi: 10.1093/ibd/izaf029.
4
Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions.炎症性肠病中预测反应的发病机制与精准医学：进展与未来方向
eGastroenterology. 2024 Jan 18;2(1):e100006. doi: 10.1136/egastro-2023-100006. eCollection 2024 Jan.
5
Understanding the therapeutic toolkit for inflammatory bowel disease.了解炎症性肠病的治疗方法。
Nat Rev Gastroenterol Hepatol. 2025 Jan 31. doi: 10.1038/s41575-024-01035-7.
6
Predictive Value of Albumin to Fibrinogen Ratio and CALLY Index for Diagnosis of Ulcerative Colitis and Mucosal Healing After Vedolizumab Treatment.白蛋白与纤维蛋白原比值及CALLY指数对溃疡性结肠炎诊断及维多珠单抗治疗后黏膜愈合的预测价值
J Inflamm Res. 2025 Jan 14;18:589-600. doi: 10.2147/JIR.S500600. eCollection 2025.
7
Early intervention with Ustekinumab is associated with higher rates of clinical and endoscopic remission in patients with Crohn's disease.对于克罗恩病患者，早期使用乌司奴单抗进行干预与更高的临床缓解率和内镜缓解率相关。
Therap Adv Gastroenterol. 2024 Dec 23;17:17562848241307596. doi: 10.1177/17562848241307596. eCollection 2024.
8
mHealth Physical Activity and Patient-Reported Outcomes in Patients With Inflammatory Bowel Diseases: Cluster Analysis.移动医疗在炎症性肠病患者中的体力活动和患者报告结局：聚类分析。
J Med Internet Res. 2024 Sep 24;26:e48020. doi: 10.2196/48020.
9
Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease.乌司奴单抗谷浓度、血清白细胞介素-22和抑瘤素M水平与克罗恩病患者临床及生化指标的相关性
J Clin Med. 2024 Mar 7;13(6):1539. doi: 10.3390/jcm13061539.
10
Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab.克罗恩病患者血清蛋白质组学揭示了英夫利昔单抗的应答特征，但不是维得利珠单抗。
Inflamm Bowel Dis. 2024 Sep 3;30(9):1536-1545. doi: 10.1093/ibd/izae016.
本文引用的文献
1
Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Prediction and Prevention of Inflammatory Bowel Disease.ECCO 第七届科学研讨会成果：炎症性肠病的精准医学——预测和预防。
J Crohns Colitis. 2021 Sep 25;15(9):1443-1454. doi: 10.1093/ecco-jcc/jjab048.
2
Understanding the Molecular Drivers of Disease Heterogeneity in Crohn's Disease Using Multi-omic Data Integration and Network Analysis.利用多组学数据整合和网络分析理解克罗恩病的疾病异质性的分子驱动因素。
Inflamm Bowel Dis. 2021 May 17;27(6):870-886. doi: 10.1093/ibd/izaa281.
3
Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?监测炎症性肠病患者的 vedolizumab 和 ustekinumab 药物水平：炒作还是希望？
Curr Opin Pharmacol. 2020 Dec;55:17-30. doi: 10.1016/j.coph.2020.09.002. Epub 2020 Oct 9.
4
Underpowered PANTS: A Response to the Conclusions of "Extended Analysis Identifies Drug-Specific Association of Two Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab".效力不足的 PANTS：对“扩展分析确定两种不同 HLA II 类单倍型与阿达木单抗和英夫利昔单抗免疫原性发展的药物特异性关联”结论的回应
Gastroenterology. 2021 Jan;160(1):470-471. doi: 10.1053/j.gastro.2020.05.102. Epub 2020 Oct 3.
5
Sex steroids and autoimmune rheumatic diseases: state of the art.性激素与自身免疫性风湿病：最新进展。
Nat Rev Rheumatol. 2020 Nov;16(11):628-644. doi: 10.1038/s41584-020-0503-4. Epub 2020 Oct 2.
6
Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease.综述：肠道微生物群如何反映炎症性肠病的疾病活动度并影响治疗结果。
Aliment Pharmacol Ther. 2020 Nov;52(9):1453-1468. doi: 10.1111/apt.16096. Epub 2020 Sep 24.
7
Disease Activity Patterns of Crohn's Disease in the First Ten Years After Diagnosis in the Population-based IBD South Limburg Cohort.发病十年内基于人群的炎症性肠病南林堡队列研究中克罗恩病的疾病活动模式。
J Crohns Colitis. 2021 Mar 5;15(3):391-400. doi: 10.1093/ecco-jcc/jjaa173.
8
Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK.临床试验[与困境]：COVID-19 对英国 IBD 临床研究活动的直接影响。
J Crohns Colitis. 2020 Dec 2;14(12):1769-1776. doi: 10.1093/ecco-jcc/jjaa137.
9
Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.依特立珠单抗治疗溃疡性结肠炎和克罗恩病：3 期临床项目概述。
Adv Ther. 2020 Jul;37(7):3417-3431. doi: 10.1007/s12325-020-01366-2. Epub 2020 May 22.
10
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.1 年深度缓解可预防早期克罗恩病进展。
Gastroenterology. 2020 Jul;159(1):139-147. doi: 10.1053/j.gastro.2020.03.039. Epub 2020 Mar 26.
Zotero 插件